ABBV•benzinga•
AbbVie Q1 2025 Earnings Include $248M IPR&D And Milestones Expense; For Q1 Sees Unfavorable Impact Of $0.13 To GAAP And Non-GAAP EPS; Q1 2025 Adjusted EPS Guidance $2.34-$2.38 Vs $2.51 Est.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga